Around 1 out of 2000 to 2500 live female births are affected by Turner syndrome. Studies reveal that there are nearly 70,000 females with Turner syndrome in the United States. It is reported that the frequency of the disorder is not influenced by racial and ethnic factors. Current therapies, such as growth hormone for height and estrogen replacement for puberty, do not address all the health issues faced by Turner syndrome patients. Thus, there is a need for drug pipeline expansion for the disorder to accommodate the diverse and complex needs of affected individuals.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to Turner syndrome.
Growth hormone therapy is often prescribed to increase height and is usually started in childhood. Estrogen replacement therapy in the form of pills, patches, or injections is given during the early teenage years to promote the development of secondary sexual characteristics. Increased emphasis on the development of drugs that can prevent or mitigate the onset of complications associated with Turner syndrome is expected to significantly improve the quality of life of the patients and also positively impact the disease pipeline landscape.
This product will be delivered within 3-5 business days.
Report Coverage
The Turner Syndrome Drug Pipeline Insight Report by the publisher gives comprehensive insights into Turner syndrome drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Turner syndrome. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The Turner syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Turner syndrome.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to Turner syndrome.
Turner Syndrome Drug Pipeline Outlook
Turner syndrome, also known as monosomy X, 45X, or Ullrich-Turner syndrome, is a rare genetic condition in which one of the X chromosomes in females is completely or partially missing. Common symptoms include a webbed neck, short stature, broad chest, and low-set ears, among others. This genetic disorder is considered the most common sex chromosomal abnormality in females, with the patients facing emotional and psychological challenges besides various co-morbid conditions.Growth hormone therapy is often prescribed to increase height and is usually started in childhood. Estrogen replacement therapy in the form of pills, patches, or injections is given during the early teenage years to promote the development of secondary sexual characteristics. Increased emphasis on the development of drugs that can prevent or mitigate the onset of complications associated with Turner syndrome is expected to significantly improve the quality of life of the patients and also positively impact the disease pipeline landscape.
Turner Syndrome - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Turner syndrome drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene Therapy
By Route of Administration
- Oral
- Parenteral
- Others
Turner Syndrome - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for Turner syndrome.Turner Syndrome - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under Turner syndrom pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptide, polymer, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Turner syndrome.Turner Syndrome Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the Turner Syndrome drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Turner syndrome clinical trials:- Novo Nordisk A/S
- Ascendis Pharma Endocrinology Division A/S
- Eli Lilly and Company
- Merck KGaA
- Ferring Pharmaceuticals
- Genentech, Inc.
- Sequenom, Inc.
- LG Chem
Turner Syndrome - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Drug: Somapacitan
Sponsored by Novo Nordisk A/S, this Phase III study aims to evaluate the safety and efficacy of somapacitan, a new growth hormone medicine, in children either born small for gestational age or with Turner syndrome, idiopathic short stature, or Noonan syndrome. The study will span for a course of 3 years, with the administration of somapacitan once a week.Biological: Lonapegsomatropin, Drug: Somatropin
The objective of this randomized, open-label, active-controlled clinical study is to examine the efficacy, safety, and tolerability of different dose levels of lonapegsomatropin (administered once a week) in comparison to daily somatropin in an estimated 48 prepubertal subjects with Turner syndrome. This Phase II clinical trial is conducted by Ascendis Pharma Endocrinology Division A/S.Reasons To Buy This Report
The Turner Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Turner syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Turner syndrome pipeline insights.Key Questions Answered in the Turner Syndrome - Pipeline Insight Report
- What is the current landscape of Turner syndrome pipeline drugs?
- How many companies are developing Turner syndrome drugs?
- How many phase III and phase IV drugs are currently present in Turner syndrome pipeline drugs?
- Which companies/institutions are leading the Turner syndrome drug development?
- What is the efficacy and safety profile of Turner syndrome pipeline drugs?
- What are the opportunities and challenges present in the Turner syndrome drug pipeline landscape?
- Which company is conducting major trials for Turner syndrome drugs?
- What geographies are covered for Turner syndrome clinical trials?
- What are emerging trends in Turner syndrome clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Turner Syndrome Pipeline
4 Patient Profile: Turner Syndrome Pipeline
5 Turner Syndrome Pipeline: Epidemiology Snapshot
6 Turner Syndrome Pipeline: Market Dynamics
7 Turner Syndrome Pipeline: Key Facts Covered
8 Turner Syndrome Pipeline, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Turner Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Turner Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Turner Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Turner Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Turner Syndrome, Key Drug Pipeline Companies
